Ramius V&O Acquisition LLC, a subsidiary of Ramius LLC, today announced that Cypress Bioscience, Inc. CYPB has rejected its fully financed offer to acquire all of Cypress' outstanding Common Stock in a negotiated transaction for $6.00 per share in cash.
Market News and Data brought to you by Benzinga APIs© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
